<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Isolated isochromosome (17q) is a rare cytogenetic abnormality in Philadelphia chromosome-negative myeloid <z:hpo ids='HP_0002664'>neoplasms</z:hpo>, usually myelodysplastic and/or myeloproliferative <z:hpo ids='HP_0002664'>neoplasms</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/MPN) </plain></SENT>
<SENT sid="1" pm="."><plain>De novo <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) with isochromosome 17q has rarely been reported </plain></SENT>
<SENT sid="2" pm="."><plain>The frequency of genetic mutations is unknown </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: The authors assessed clinicopathologic, immunophenotypic, and molecular genetic features of 22 myeloid <z:hpo ids='HP_0002664'>neoplasms</z:hpo> with isolated isochromosome 17q </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Fourteen patients presented as <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/MPN; 8 as de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Most presented with <z:hpo ids='HP_0001974'>leukocytosis</z:hpo>, <z:hpo ids='HP_0001903'>anemia</z:hpo>, <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo>, and <z:hpo ids='HP_0001744'>splenomegaly</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Morphologically, <z:hpo ids='HP_0000001'>all</z:hpo> showed myelodysplastic and myeloproliferative features, including pseudo-Pelger-Huet-like neutrophils, micromegakaryocytic <z:mpath ids='MPATH_134'>hyperplasia</z:mpath>, hypercellularity, <z:mp ids='MP_0003045'>fibrosis</z:mp>, and <z:hpo ids='HP_0011001'>osteosclerosis</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>Blasts were increased (median, 40% in de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>; 9% in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/MPN) </plain></SENT>
<SENT sid="8" pm="."><plain>Immunohistochemical assessment of proliferation and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> rates in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> were similar to a matched group without isochromosome 17q </plain></SENT>
<SENT sid="9" pm="."><plain>In most patients, isochromosome 17q occurred at time of blast transformation or disease progression </plain></SENT>
<SENT sid="10" pm="."><plain>DNA sequencing revealed no mutation in the uninvolved TP53 allele </plain></SENT>
<SENT sid="11" pm="."><plain>Mutational analyses showed rare mutations in NRAS (3 of 10), FLT3 (2 of 16), and JAK2 (1 of 18), and no mutations in NPM1 (0 of 15), KIT (0 of 4), and CEBPA (0 of 4) </plain></SENT>
<SENT sid="12" pm="."><plain>The median overall survival was 14.5 months for de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, and 11.0 months for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/MPN </plain></SENT>
<SENT sid="13" pm="."><plain>With a median follow-up of 8.5 months (range, 1.5-107 months), 15 died of disease, 6 had persistent disease, and 1 was in remission after bone marrow transplantation </plain></SENT>
<SENT sid="14" pm="."><plain>CONCLUSIONS: The authors conclude that myeloid <z:hpo ids='HP_0002664'>neoplasms</z:hpo> with isolated isochromosome 17q represent a distinct clinicopathologic entity with myelodysplastic and myeloproliferative features, high risk of leukemic transformation, and <z:mp ids='MP_0002169'>wild-type</z:mp> TP53 </plain></SENT>
</text></document>